Home
overview

This year SAE’s 3rd annual Oligonucleotide Therapeutics and Delivery conference will showcase recent advances in oligonucleotide development, regulatory requirements and CMC considerations, strategies to enhance oligonucleotide discovery and targeting and optimised delivery techniques for oligonucleotide-based therapies, in the hope to continue to drive forward the field of oligonucleotide drug development. Join us on the 11-12 September.

 The only event that will:

Showcase new representation and insights from the following big pharma companies, with a high level agenda focussing on driving industry advancement, whilst also offering benchmarking and networking opportunities for leading figures in the industry.
• Eli lilly
• Moderna
• BioNTech
• Alnylam Pharmaceuticals
• GSK
• Merck
• Servier
• AstraZeneca
• Roche
• Bayer

What’s different this year:

This year the conference will be chaired by two leaders in the field of oligonucleotide therapeutics and delivery: Joseph R. Martinelli, Executive Director, Genetic Medicine, Eli Lilly and Company & Edward Hennessy, Senior Director, Discovery Chemistry, Moderna.

 

  • Examine recent developments in CMC practices and key considerations for oligonucleotide manufacturing, with insights
    from leading industry experts, including Roche,  GSK and many more
  • Enhance your knowledge of the latest innovations in early stage discovery, with key case studies from leading biotechs including
    Arthex Bio, Altamira Therapeutics and Rnatics
  • Engage in current trends and solutions for optimising delivery techniques and target specificity beyond the liver
  • Explore developments in new novel applications of ASOs and expand on current discovery chemistry techniques

Pharma and Biotech Directors, Managers and Heads of Departments of:
• RNA
• Genetic Medicine
• Oligonucleotide Discovery
• RNA Discovery
• New Modalities
• RNA Biology
• RNA Formulation and Delivery
• Targeted Delivery
• Clinical Development
• Pre-Clinical Development
• Oligonucleotide Chemistry
• Drug Discovery
• Target Discovery
• Medicinal Chemistry
• RNA Development
• RNA Vaccines
• RNA Biochemistry 

& others, book here today! 

 

Advirna; Aptamer group; Argonaute RNA Limited; ARNAY Sciences; AstraZeneca; AstraZeneca AB R&D; Astrazeneca Neuroscience; AstraZeneca R&D; AstraZeneca R&D Mölndal; Avidity Biosciences; Avidity Biosciences Inc.; Bioinformatics, Stoke Therapeutics; Bio-Techne Ltd; Croda Europe Ltd; Eli Lilly; Eli Lilly and Company; Envisagenics; Envisagenics Inc; F. Hoffmann-La Roche Ltd.; GenScript Biotech (Netherlands) B.V.; HAYA Therapeutics; Imperial College; InteRNA Technologies BV; Medical Research Council; Miescher Pharma GmbH; MiNA Therapeutics; MiNa Therapeutics Ltd; NEUWAY Pharma; NOXXON Pharma AG; Nucleic Acid Therapy Accelerator; Onxeo S.A.; PYC Therapeutics Ltd; Rasayan Inc.; Roche; Royal College of Surgeons in Ireland; Royal College of Surgeons Ireland (RCSI); Sapreme Technologies B.V.; Sarepta Therapeutics Germany GmbH; Senn Chemicals AG; Silence Therapeutics AG; Silenseed; Sirnaomics, Inc; Skorpio; STERIS Solutions Limited; Stoke Therapeutics Inc; Tosoh Bio Science GmbH; Tosoh Bioscience GmbH; TranSINE Therapeutics; University College Dublin; University College London;

Conference programme

8:00 Registration & Coffee

9:00 Chairman's Opening Remarks

Joseph Martinelli

Joseph Martinelli, Executive Director, Eli Lilly
View Bio

Edward Hennessy

Edward Hennessy, Senior Director, Discovery Chemistry, Moderna
View Bio

9:10 Genetic medicine: state of the art, frontiers and current research

Joseph Martinelli

Joseph Martinelli, Executive Director, Eli Lilly
View Bio

  • Addressing key challenges at the forefront of the next generation of genetic medicines
  • The role of Nucleic acid innovation in the development of RNA therapeutics
  • Exploring delivery innovation as a crucial component in the advancement of RNA therapies
  • 9:50 Role of Clinical Pharmacology in the Development of Novel RNA modalities

    Venkatesh Pilla Reddy

    Venkatesh Pilla Reddy, Director of Clinical Pharmacology and Pharmacometrics, AstraZeneca
    View Bio

  • Delving into model informed therapeutic development for novel therapies including self-amplifying RNA technology
  • Reviewing application and benefi ts of Clinical Pharmacology in AAV, mRNA and self-amplifying RNAs based therapies
  • Next steps: assessing the current fi eld and future work required for approval of novel RNA vaccines and immunotherapies
  • 10:30 Morning Coffee

    11:00 Introduction to RNA activation to restore cell function

    Nagy Habib

    Nagy Habib, Head of HBP Surgery, Co-Founder, Imperial College
    View Bio

  • RNA activation for treatment of acquired and rare genetic diseases
  • RNA aptamers for oligonucleotide delivery
  • Discussion of increasing oligonucleotide drugs and why this matters
  • 11:40 OligoPhore and SemaPhore for extrahepatic delivery of therapeutic RNA

    Covadonga Paneda

    Covadonga Paneda, Chief Development Officer, Altamira Therapeutics
    View Bio

  •  Description of OligoPhore and SemaPhore platforms for delivery therapeutic RNA
  • Rapid and extensive pH-dependent release of RNA from endosomal resulting in effective delivery into cells
  • Distribution of therapeutic RNA into extrahepatic tissues
  • Examples of effective RNA activity in animal models of disease
  • 12:20 Networking Lunch

    13:20 Optimizing RNAi applications through novel AI technologies

    Yaniv Erlich

    Yaniv Erlich, CEO, Eleven Therapeutics
    View Bio

  •  Utilising massively parallel combinatorial searches and AI algorithms to unleash the full power of RNAi
  • Reviewing the structure-activity relationship (SAR) of RNAi molecules to enhance drug safety and efficacy
  • Developing the next generation of RNAi therapeutics to silence the disease-causing genes
  • 14:00 Development of a lipophilic-conjugated antimiR to treat Myotonic Dystrophy type 1 (DM1)

    Judith Walker

    Judith Walker, Chief Medical Officer, Arthex Biotech

  • DM1 is a rare disease with a complex but well understood pathophysiology which leads to reduced availability of regulatory MBNL proteins due to an expansion of non-coding CTG repeats in the DMPK gene
  • Arthex has developed a lipophilic-conjugated antimir-23b oligo (ATX-01), that acts on both MBNL protein and DMPK mRNA  levels, alleviating functional and molecular signs of the disease in human cell and animal models
  • ATX-01 is remarkably safe and well-tolerated in relevant toxicology species including NHP, and the therapeutic window supports testing of ascending doses in human patients.
  • Arthex will initiate a multinational PhI/IIa clinical trial of patients with DM1, later this year

     

  • 14:40 Afternoon Tea

    15:10 CMC Considerations for stable LNP Manufacturing

    Michael Keller

    Michael Keller, Expert Scientist, Roche
    View Bio

  • Overview of key CMC regulatory challenges
  • Regulatory strategies for use of platform data and prior knowledge
  • Future regulatory considerations to enhance oligonucleotide development and manufacturing
  • 15:50 Manufacturing therapeutic oligonucleotides - the challenges of scale, cost and sustainability

    David Tew

    David Tew, Senior Scientific Director, GSK

  • Solid phase vs liquid phase methods
  • New chemistries for oligonucleotide synthesis
  • The use of enzymes in oligonucleotide synthesis
  • Thoughts on how these new methods will help to address cost and sustainability issues
  • 16:30 Chairman’s Closing Remarks and Close of Day One

    Joseph Martinelli

    Joseph Martinelli, Executive Director, Eli Lilly
    View Bio

    Edward Hennessy

    Edward Hennessy, Senior Director, Discovery Chemistry, Moderna
    View Bio

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Joseph Martinelli

    Joseph Martinelli, Executive Director, Eli Lilly
    View Bio

    Edward Hennessy

    Edward Hennessy, Senior Director, Discovery Chemistry, Moderna
    View Bio

    9:10 Discovery of novel amino lipids for mRNA delivery

    Edward Hennessy

    Edward Hennessy, Senior Director, Discovery Chemistry, Moderna
    View Bio

  •  An introduction to lipid nanoparticles (LNPs) for the delivery of nucleic acids, with a focus on the role of  the amino lipid component
  • Medicinal chemistry strategies for optimizing lipid/LNP physical properties, pharmacokinetics, and biological performance
  • Utilization of computational modelling to guide the design of  improved delivery vehicles for mRNA
  • 9:50 Identifying high value targets for RNAi therapeutics using human genetics

    Paul Nioi

    Paul Nioi, Vice President, Discovery and Translational Research, Alnylam
    View Bio

  •  RNAi is a powerful means of accessing previously undruggable targets
  • Identifying suitable targets for RNAi-mediated knockdown can be challenging
  • Human genetics is a very valuable approach for target identification
  • Case study on identifi cation of a new RNAi target for T2D using genetics
  • 10:30 Morning Coffee

    11:00 Data Driven Optimization of Oligonucleotide Sequence Design

    Thierry Dorval

    Thierry Dorval, Head of Data Sciences & Data Management, Institut de Recherches Servier
    View Bio

  •  Optimising drug discovery using computational and knowledge graph approaches
  • Case Studies from Servier’s ASOS design approach
  • Ensuring adverse effect identifi cation using AI approaches
  • 11:40 Targeting of RNA beyond LNP

    Thomas Frischmuth

    Thomas Frischmuth, CEO, rnatics GmbH
    View Bio

  •  Conjugation of ligands to RNA species
  • Ligands targeting in particular sugar receptors
  • RNA species of LNA, siRNA and mRNA origin
  • Targeting of lung makrophages
  • 12:20 Networking Lunch

    13:20 PANEL DISCUSSION: Reviewing Oligonucleotide therapeutics as the next generation of genetic medicines

  •  Discussing current drug like properties of oligo-based medicines: Cargo (e.g., properties of siRNA) vs carriers (e.g., properties of LNPs)
  • Dissecting the challenges associated with targeted delivery of oligonucleotides
  • Understanding the future direction of ASOs and oligo-based based drugs, with a focus on emerging, novel oligonucleotides
  • Kaushik Thanki

    Kaushik Thanki, Director Early-Stage Formulation Process Development, BioNTech SE

    David Tew

    David Tew, Senior Scientific Director, GSK

    Thierry Dorval

    Thierry Dorval, Head of Data Sciences & Data Management, Institut de Recherches Servier
    View Bio

    Florian Mann

    Florian Mann, Lab Head Drug Targeting & Vectors, Bayer AG Pharmaceuticals

    14:00 Advanced Analytical Characterization of mRNA LNPs

    Lee Klein

    Lee Klein, Principal Scientist, Merck & Co., Inc
    View Bio

  • Methods to characterize LNP surfaces including:
  • PEG lipid surface saturation
  • PZC for charge distribution
  • Surface binding
  • 14:40 Afternoon Tea

    15:10 Non-viral delivery of RNA therapeutics

    Florian Mann

    Florian Mann, Lab Head Drug Targeting & Vectors, Bayer AG Pharmaceuticals

  • Overview of the RNA delivery fi eld
  • How does structure affect function in LNPs?
  • Non-viral delivery beyond liver
  • 15:50 Protein-based nanocapsules for therapeutic RNA delivery to the brain

    Ekkehard Leberer

    Ekkehard Leberer, Scientific Advisor, NEUWAY Pharma
    View Bio

  •  The presentation will describe the generation and the use of protein-based nanocapsules to deliver a broad range of therapeutic RNAs across the blood-brain barrier.
  • The therapeutic potential of this delivery technology will be illustrated for the treatment of monogenetic CNS disorders such as metachromatic leukodystrophy (MLD), a lysosomal storage
    disease
  • 16:30 Chairman’s Closing Remarks and Close of Day Two

    Joseph Martinelli

    Joseph Martinelli, Executive Director, Eli Lilly
    View Bio

    Edward Hennessy

    Edward Hennessy, Senior Director, Discovery Chemistry, Moderna
    View Bio

    +

    Chief Development Officer
    Altamira Therapeutics
    Senior Scientific Director
    GSK
    Senior Director, Discovery Chemistry
    Moderna
    Scientific Advisor
    NEUWAY Pharma
    Lab Head Drug Targeting & Vectors
    Bayer AG Pharmaceuticals
    Executive Director
    Eli Lilly
    Chief Medical Officer
    Arthex Biotech
    Director Early-Stage Formulation Process Development
    BioNTech SE
    Principal Scientist
    Merck & Co., Inc
    Expert Scientist
    Roche
    Head of HBP Surgery, Co-Founder
    Imperial College
    Vice President, Discovery and Translational Research
    Alnylam
    Head of Data Sciences & Data Management
    Institut de Recherches Servier
    CEO
    rnatics GmbH
    Director of Clinical Pharmacology and Pharmacometrics
    AstraZeneca
    CEO
    Eleven Therapeutics

    VENUE

    Hilton London Kensington

    179-199 Holland Park Avenue, London, United Kingdom

    At the heart of the Holland Park district, our hotel is 10 minutes from Westfield London shopping center. We're blocks from Shepherd's Bush Underground station, linking to central London, and Kensington Palace and Gardens are two miles from us. Enjoy 24-hour access to our fitness center.

     
    Join us in WestEleven for hearty buffet breakfast, a great way to start the day! Our Avenue Bar and Lounge serves light bites throughout the day as well as a delicious, seasonal dining menu.”

    A number of our clients have been approached by third party organisations offering to book hotel rooms. We would advise that you do not book through them as they are not representing the SMi Group. SMi Group books all hotel rooms directly. If you are approached by a third party organisation then please contact us before making any bookings. If you have already booked a hotel room using a third party organisation, we would highly recommend contacting the hotel you were booked into to ensure a booking has been made for you. We would also advise you to please check the terms and conditions of the booking carefully.
    HOTEL BOOKING FORM

    SAVE TO


    Outlook Calendar  OUTLOOK CALENDAR
    Google Calendar  GOOGLE CALENDAR
    ICal Calendar  ICAL CALENDAR
    Yahoo! Calendar  YAHOO! CALENDAR

    Hilton London Kensington

    179-199 Holland Park Avenue
    London W11 4UL
    United Kingdom

    Hilton London Kensington

    At the heart of the Holland Park district, our hotel is 10 minutes from Westfield London shopping center. We're blocks from Shepherd's Bush Underground station, linking to central London, and Kensington Palace and Gardens are two miles from us. Enjoy 24-hour access to our fitness center.

     
    Join us in WestEleven for hearty buffet breakfast, a great way to start the day! Our Avenue Bar and Lounge serves light bites throughout the day as well as a delicious, seasonal dining menu.”
    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SAE Media Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@saemediagroup.com

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SAE Media Group

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SAE Media Group , Ground Floor, India House, 45 Curlew Street, London, SE1 2ND, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smgconferences.com Email: events@saemediagroup.com
    Registered in England - SMi Group Ltd trading as SAE Media Group




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SAE Media Group.
    Full details of our privacy policy can be found here https://www.smgconferences.com/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data@smgconferences.com.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smgconferences.com/opt-out

    Fill in your details to download the brochure

    By ticking above you are consenting to receive information by email from SAE Media Group.
    Full details of our privacy policy can be found here https://www.smgconferences.com/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data@smgconferences.com.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smgconferences.com/opt-out